# Budesonide for Induction of Remission in Incomplete Microscopic Colitis

> **NCT02142634** · PHASE3 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 44 (actual)

## Conditions studied

- Incomplete Microscopic Colitis

## Interventions

- **DRUG:** Budesonide granules 9 mg
- **DRUG:** Placebo granules

## Key facts

- **NCT ID:** NCT02142634
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2020-02
- **Final completion:** 2020-02
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2020-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02142634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02142634, "Budesonide for Induction of Remission in Incomplete Microscopic Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02142634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*